CLIMB THAL-111/SCD-121: Phase I/II Studies of CTX001 for Transfusion-Dependent β-Thalassemia and Sickle Cell Disease

December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Among the first 10 study participants with ≥ 3 months of follow-up, CTX001 infusion achieved cessation of pRBC transfusions for TDT patients, and eliminated veno-occlusive events for severe SCD patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 233 KB
Released: December 16, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Epizyme Inc.
GlaxoSmithKline
Incyte Corporation
Janssen Biotech, Inc.
Karyopharm Therapeutics Inc.
Novartis
PharmaEssentia Corp.
Seagen
Takeda Oncology

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the expanding treatment options for hemophilia A & B

Stacy Croteau Headshot Stacy E. Croteau, MD, MMS
Program Director
Guy A. Young, MD
Program Director
Released: January 25, 2023

Data on JAK2 V617F molecular response from a study of ruxolitinib in patients with polycythemia vera or essential thrombocythemia, from ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 19, 2022

New data from APPLY-PNH study of iptacopan in patients with paroxysmal nocturnal hemoglobinuria, presented at ASH 2022 and reported by Clinical Care Options (CCO)

Released: December 17, 2022

Results from phase II trial of second-in-class oral factor D inhibitor vemircopan in previously untreated patients with PNH, presented at ASH 2022 and reported by Clinical Care Options( CCO)

Released: December 16, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings